<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360070</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT04360070</nct_id>
  </id_info>
  <brief_title>The Application of Ketamine for Sedation in Patients With Cardiac Arrest</brief_title>
  <official_title>The Application of Ketamine for Sedation in Patients With Cardiac Arrest: Feasibility, Safety, and Potential Impact on Neurological Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fraser Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fraser Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent evidence suggests ketamine may attenuate harmful cellular cascades taking place after&#xD;
      brain injury that result in permanent damage. The investigators are interested in researching&#xD;
      the application of this in the setting of cardiac arrest. Following cardiac arrest, the brain&#xD;
      is deprived oxygen for a period of time, leading to the imitation of these harmful cellular&#xD;
      processes. The investigators hypothesize that patients who receive ketamine as part of their&#xD;
      standard sedation procedures during cardiac arrest treatment have better neurological&#xD;
      functioning compared to those who do not.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility Data</measure>
    <time_frame>through study completion, an average of 6 months.</time_frame>
    <description>To test the appropriateness of the eligibility criteria by recording enrolment rates of eligible patients, test the randomization assignment procedures by evaluating for any difference in baseline characteristics between groups, and test adequate adherence to protocol by recording time taken to administer intervention during sedation procedures.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cardiac Arrest, Out-Of-Hospital</condition>
  <condition>Ketamine</condition>
  <condition>Neurologic Manifestations</condition>
  <arm_group>
    <arm_group_label>Ketamine Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the ketamine arm will receive ketamine as part of their sedation medications during their cardiac arrest treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to the control arm will not receive ketamine as part of their sedation medications during their cardiac arrest treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Hydrochloride</intervention_name>
    <description>Parenteral General Anesthetic</description>
    <arm_group_label>Ketamine Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All out-of-hospital cardiac arrests (OHCA) with a &quot;shockable rhythm&quot; (ventricular&#xD;
             fibrillation, pulseless ventricular tachycardia) that present to the Royal Columbian&#xD;
             Hospital. The patient may be either in active cardiac arrest with shockable rhythm or&#xD;
             may have achieved Return of Spontaneous Circulation (ROSC).&#xD;
&#xD;
          -  Over 19 years of age&#xD;
&#xD;
          -  Patients requiring sedation based on the assessment of the resuscitating physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other type of cardiac arrest&#xD;
&#xD;
          -  Any history of previous, pre-existing neurological deficit&#xD;
&#xD;
          -  Started on Extracorporeal Membrane Oxygenation (ECMO)&#xD;
&#xD;
          -  Duration of cardiac arrest without ROSC is greater than 30 consecutive minutes&#xD;
&#xD;
          -  Known contraindication or hypersensitivity to ketamine&#xD;
&#xD;
          -  Awake patient or no standard sedation or no intubation required&#xD;
&#xD;
          -  Inability to obtain deferred consent&#xD;
&#xD;
          -  Currently enrolled in any other research study involving drugs or devices&#xD;
&#xD;
          -  Patients who are pregnant&#xD;
&#xD;
          -  Patients who are prisoners&#xD;
&#xD;
          -  Patients residing in Long Term Care (LTC) facilities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>George Medvedev, MD</last_name>
    <phone>604 759 2140</phone>
    <email>drmedvedev@shaw.ca</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fraser Health</investigator_affiliation>
    <investigator_full_name>George Medvedev</investigator_full_name>
    <investigator_title>Head of Neurology</investigator_title>
  </responsible_party>
  <keyword>Pilot Study</keyword>
  <keyword>Single-Centre</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurologic Manifestations</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

